GlassScriptPhysician profile
Aditya Mehta
NPI 1699194159
$6,087.47
in general payments reported to CMS, 2019-2025
26 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $377 · 2021: $816 · 2022: $1,242 · 2023: $961 · 2024: $801 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322 · Travel and Lodging: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,321.72 |
| Travel and Lodging | $716.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,130.74 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $930.36 | 2019-2025 | |
| Abbott Laboratories | $856.25 | 2023-2025 | Cardiomems, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $598.15 | 2019-2024 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $410.51 | 2020-2025 | Lifevest |
| Pfizer INC. | $345.56 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $315.25 | 2021-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $247.66 | 2020-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.66 | 2019-2025 | Jardiance |
| Abbvie INC. | $186.75 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.72 | 2022-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $137.47 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $82.98 | 2023 | Inpefa |
| Advanced Respiratory, INC | $79.83 | 2019-2021 | |
| Recor Medical INC | $69.23 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $60.60 | 2021-2025 | |
| Boston Scientific Corporation | $57.41 | 2019-2020 | |
| Gilead Sciences, INC. | $36.07 | 2022 | |
| Amgen INC. | $32.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.19 | 2022 | |
| Csl Behring | $28.01 | 2023 | Kcentra |
| Ucb, INC. | $24.75 | 2022 | |
| Nestle Healthcare Nutrition INC. | $19.10 | 2021 | |
| Baxter Healthcare | $18.34 | 2023 | Hillrom - Life 2000 Ventilation System |
| Merck Sharp & Dohme LLC | $17.73 | 2023 | Verquvo |
| Novo Nordisk INC | $17.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.